{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:06:58Z","timestamp":1789538818253,"version":"build-2803163510"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>Giant cell urothelial carcinoma (GCUC) is an exceedingly rare histologic subtype with 50+ reported cases. To date, 3 case series have been reported. Scant chemotherapy and immunotherapy responses were reported with variable results. We report the largest GCUC series, including 27 GCUC and 27 matched control urothelial carcinoma (CoUC) patients, most (&gt;90%) of whom had more than 5 years of follow-up, including neoadjuvant and adjuvant therapy status. We further characterized the nuclear size ratio of giant tumor cells to background tumor cells and analyzed urothelial differentiation markers (GATA3, CK5\/6), p53, tumor-infiltrating lymphocytes (CD19 and CD3), and therapeutic targets (TROP2, Nectin4, PDL1, and HER2). Morphometric analysis of giant tumor cells demonstrated that they were, on average, 12 times larger than surrounding nongiant tumor cells. GCUC showed many histologic and immunophenotypic features similar to CoUC. GCUC was enriched for higher stages (T3\/4 and metastatic disease) than CoUC and showed a trend toward worse OS than conventional urothelial carcinoma, but was similar to urothelial carcinoma with variant histology. GCUC included 3 low-stage (T1\/2) patients, who had significantly worse OS than low-stage CoUC, suggesting early extensive workup and oncologic intervention. Chemotherapy slightly improved OS in both GCUC and CoUC patients without statistical significance. Compared with CoUC, GCUC appeared to have more tumor-infiltrating T cells, but without statistical significance. There were no expression differences in TROP2, Nectin4, PDL1, and HER2. However, a subset of GCUC patients might benefit from target therapies (PDL1, Nectin4), warranting more cohort studies.<\/jats:p>","DOI":"10.1097\/pas.0000000000002576","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T09:00:10Z","timestamp":1780909210000},"page":"1184-1194","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Giant Cell Urothelial Carcinoma"],"prefix":"10.1097","volume":"50","author":[{"given":"Huili","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pathology, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Akbari","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Schuler","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Johns Hopkins University, Baltimore, MD"},{"name":"Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Salgado Esteves","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"Pienta","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Johns Hopkins University, Baltimore, MD"},{"name":"Department of Urology, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burles A.","family":"Johnson III","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Johns Hopkins University, Baltimore, MD"},{"name":"Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD"},{"name":"Department of Urology, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezra","family":"Baraban","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University, Baltimore, MD"},{"name":"Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0990-1115","authenticated-orcid":false,"given":"Andres","family":"Matoso","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University, Baltimore, MD"},{"name":"Department of Oncology, The Johns Hopkins University, Baltimore, MD"},{"name":"Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD"},{"name":"Department of Urology, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"R1-20260916","doi-asserted-by":"crossref","first-page":"9111","DOI":"10.1186\/1757-1626-2-9111","article-title":"Urinary bladder carcinoma with triplicate differentiations into giant cell sarcomatoid carcinoma, squamous cell carcinoma, and papillary urothelial transitional cell carcinoma: a case report","volume":"2","author":"Terada","year":"2009","journal-title":"Cases J"},{"key":"R2-20260916","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.path.2022.07.003","article-title":"Urothelial carcinoma: divergent differentiation and morphologic subtypes","volume":"15","author":"Gandhi","year":"2022","journal-title":"Surg Pathol Clin"},{"key":"R3-20260916","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/PAT.0b013e3283560172","article-title":"Recently described and unusual variants of urothelial carcinoma of the urinary bladder","volume":"44","author":"Samaratunga","year":"2012","journal-title":"Pathology"},{"key":"R4-20260916","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 World Health Organization Classification of Tumors of the Urinary System and male genital organs-part b: prostate and urinary tract tumors","volume":"82","author":"Netto","year":"2022","journal-title":"Eur Urol"},{"key":"R5-20260916","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00428-024-03858-w","article-title":"Giant cell carcinoma of the urinary bladder: clinicopathologic analysis and oncological outcomes","volume":"485","author":"Portugal-Gaspar","year":"2024","journal-title":"Virchows Arch"},{"key":"R6-20260916","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.humpath.2009.02.016","article-title":"Pleomorphic giant cell carcinoma of the urinary bladder","volume":"40","author":"Lopez-Beltran","year":"2009","journal-title":"Hum Pathol"},{"key":"R7-20260916","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.prp.2013.01.008","article-title":"Polyomavirus (BK)-associated pleomorphic giant cell carcinoma of the urinary bladder: a case report","volume":"209","author":"Alexiev","year":"2013","journal-title":"Pathol Res Pract"},{"key":"R8-20260916","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/his.12785","article-title":"Pleomorphic giant cell carcinoma of the urinary bladder: an extreme form of tumour de-differentiation","volume":"68","author":"Samaratunga","year":"2016","journal-title":"Histopathology"},{"key":"R9-20260916","first-page":"377","article-title":"A case of cT3bN2M0 pleomorphic giant cell carcinoma of the bladder without recurrence after neoadjuvant chemotherapy and radical cystectomy for 4 years","volume":"65","author":"Kimura","year":"2019","journal-title":"Hinyokika Kiyo"},{"key":"R10-20260916","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00428-020-02745-4","article-title":"Clinicopathologic analysis of upper urinary tract carcinoma with variant histology","volume":"477","author":"Rolim","year":"2020","journal-title":"Virchows Arch"},{"key":"R11-20260916","first-page":"8021947","article-title":"Giant cell urothelial carcinoma of bladder","volume":"2021","author":"Wijesinghe","year":"2021","journal-title":"Case Rep Urol"},{"key":"R12-20260916","first-page":"584","article-title":"Pleomorphic giant cell carcinoma of the bladder: The diagnostic challenge of an unusual variant of urothelial carcinoma","volume":"46","author":"Fernandez de Los Reyes","year":"2022","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"R13-20260916","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/iju5.12281","article-title":"Successful treatment of metastatic bladder pleomorphic giant cell carcinoma with pembrolizumab","volume":"4","author":"Nezu","year":"2021","journal-title":"IJU Case Rep"},{"key":"R14-20260916","first-page":"446","article-title":"Pleomorphic giant cell carcinoma of urinary bladder with brain metastases despite initial response to cisplatin and gemcitabine: a case report","author":"Vega Vega","year":"2020","journal-title":"Urol Androl"},{"key":"R15-20260916","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.path.2024.10.002","article-title":"Tissue-based biomarkers important for prognostication and management of genitourinary tumors, including surrogate markers of genomic alterations","volume":"18","author":"Beauchamp","year":"2025","journal-title":"Surg Pathol Clin"},{"key":"R16-20260916","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","article-title":"Expression of Nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes","volume":"29","author":"Hoffman-Censits","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R17-20260916","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/pros.24846","article-title":"Nectin-4 expression in prostatic adenocarcinoma: an immunohistochemical study","volume":"85","author":"Baraban","year":"2025","journal-title":"Prostate"},{"key":"R18-20260916","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1200\/JCO.2015.65.9797","article-title":"Guideline on muscle-invasive and metastatic bladder cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement","volume":"34","author":"Milowsky","year":"2016","journal-title":"J Clin Oncol"},{"key":"R19-20260916","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.3748\/wjg.v22.i19.4619","article-title":"HER2 testing in gastric cancer: an update","volume":"22","author":"Abrahao-Machado","year":"2016","journal-title":"World J Gastroenterol"},{"key":"R20-20260916","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"R21-20260916","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/path.6490","article-title":"mTOR-mediated upregulation of B7-H3 in MiT\/TFE translocation renal cell carcinoma","volume":"268","author":"Li","year":"2026","journal-title":"J Pathol"},{"key":"R22-20260916","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat Methods"},{"key":"R23-20260916","doi-asserted-by":"crossref","first-page":"268919","DOI":"10.1155\/2014\/268919","article-title":"Her2+ and b-HCG producing undifferentiated gastric adenocarcinoma","volume":"2014","author":"Eivaz-Mohammadi","year":"2014","journal-title":"Case Rep Med"},{"key":"R24-20260916","first-page":"20","article-title":"The expression of beta human chorionic gonadotrophin (beta-HCG) in human urothelial carcinoma","volume":"7","author":"Venyo","year":"2010","journal-title":"Pan Afr Med J"},{"key":"R25-20260916","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/bjc.1992.62","article-title":"Beta-hCG expression by bladder cancers","volume":"65","author":"Iles","year":"1992","journal-title":"Br J Cancer"},{"key":"R26-20260916","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/ajcp\/aqaf058","article-title":"Urothelial carcinoma-are we moving beyond \u201cdivergent differentiation\u201d and \u201chistologic subtype\u201d?","volume":"164","author":"Wobker","year":"2025","journal-title":"Am J Clin Pathol"},{"key":"R27-20260916","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/ajcp\/aqaf044","article-title":"Urothelial carcinoma with osteoclast-like giant cells: an expanded immunohistochemical and molecular profile","volume":"164","author":"Rizkalla","year":"2025","journal-title":"Am J Clin Pathol"},{"key":"R28-20260916","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/10668969251363267","article-title":"Overlapping morphologic and immunophenotypic features of plasmacytoid urothelial carcinoma and urothelial carcinoma with osteoclast-like giant cells","volume":"34","author":"Rizkalla","year":"2026","journal-title":"Int J Surg Pathol"},{"key":"R29-20260916","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/modpathol.3800702","article-title":"Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance","volume":"19","author":"Guo","year":"2006","journal-title":"Mod Pathol"},{"key":"R30-20260916","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00428-019-02544-6","article-title":"Intraductal carcinoma of the prostate: a critical re-appraisal","volume":"474","author":"Varma","year":"2019","journal-title":"Virchows Arch"},{"key":"R31-20260916","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00428-022-03481-7","article-title":"Pleomorphic giant cell carcinoma of the prostate: clinicopathologic analysis and oncological outcomes","volume":"482","author":"Bile-Silva","year":"2023","journal-title":"Virchows Arch"},{"key":"R32-20260916","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.euo.2021.11.005","article-title":"TROP2 expression across molecular subtypes of urothelial carcinoma and enfortumab vedotin-resistant cells","volume":"5","author":"Chou","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"R33-20260916","doi-asserted-by":"crossref","first-page":"100753","DOI":"10.1016\/j.modpat.2025.100753","article-title":"Spatial expression of HER2, NECTIN4, and TROP-2 in muscle-invasive bladder cancer and metastases: implications for pathological and clinical management","volume":"38","author":"Dernbach","year":"2025","journal-title":"Mod Pathol"},{"key":"R34-20260916","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41585-025-01075-x","article-title":"HER2 and urothelial carcinoma: current understanding and future directions","volume":"23","author":"Raggi","year":"2026","journal-title":"Nat Rev Urol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002576","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:00:22Z","timestamp":1789538422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002576"}},"subtitle":["Morphometric Insights and Associations With Aggressive Clinical Features"],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002576","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"2026-03-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}